- Previous Close
9.77 - Open
10.28 - Bid --
- Ask --
- Day's Range
10.28 - 10.28 - 52 Week Range
0.08 - 10.28 - Volume
126 - Avg. Volume
238,757 - Market Cap (intraday)
251.817M - Beta (5Y Monthly) 1.61
- PE Ratio (TTM)
-- - EPS (TTM)
-3.50 - Earnings Date Nov 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory diseases in Norway. The company's lead clinical asset is the Bemcentinib (BGB016), an inhibitor of AXL receptor tyrosine kinase (AXL), which is in phase 1b/2a clinical trial to treat non-small cell lung cancer; and (BGBC008), which is in phase 2 clinical trial to treat second-line non-small cell lung cancer (2L NSCLC). It develops Bemcentinib, which is in preclinical trial to treat acute respiratory distress syndrome; Tilvestamab (BGB149), anti-AXL monoclonal antibody, which in phase 1 clinical trial for the treatment of ovarian cancer; and Mipasetamab Uzoptirine, which is in Phase 1 clinical trial for the treatment of solid tumors. BerGenBio ASA was incorporated in 2007 and is based in Bergen, Norway.
www.bergenbio.com15
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0RU5.L
View MorePerformance Overview: 0RU5.L
Trailing total returns as of 10/1/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0RU5.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0RU5.L
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.17%
Return on Equity (ttm)
-85.55%
Revenue (ttm)
521k
Net Income Avi to Common (ttm)
-155.4M
Diluted EPS (ttm)
-3.50
Balance Sheet and Cash Flow
Total Cash (mrq)
200.12M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-108.99M